---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-453586"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2026-11-09T21:08:26+00:00"
generated_at: "2026-11-09T21:10:21.483210+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Larimar completes rolling BLA for nomlabofusp in Friedreich's ataxia; cash $128.7M

## Summary
- Rolling Biologics License Application submitted to FDA seeking accelerated approval of nomlabofusp, a frataxin replacement therapy, for Friedreich's ataxia.
- BLA relies on skin frataxin as a potential novel surrogate endpoint; FDA previously confirmed the data package appears capable of supporting submission and review.
- Preliminary cash, cash equivalents and marketable securities of ~$128.7M as of Sept 30, 2026; quarter-end close still ongoing and figure unaudited.
- Milestones: BLA acceptance early 2027, open-label safety update Q1 2027, U.S. approval mid-2027, launch targeted Q3 2027, if approved.
- FORWARD-FA confirmatory Phase 3 enrolling: double-blind, placebo-controlled, 18 months, ages 2-40, ~two-thirds under 21; Breakthrough and Orphan designations held.

## SEC filing metadata
- accession: 0001193125-26-453586
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2026-11-09T21:08:26+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312526453586/0001193125-26-453586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312526453586/lrmr-20261109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-453586
- JSON: https://secwatch.observer/filing/0001193125-26-453586.json
- Plain text: https://secwatch.observer/filing/0001193125-26-453586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.